A network meta-analysis of 40 studies covering more than 1.9 million adults with obesity found that bariatric surgery was linked to lower all-cause mortality (HR 0.57, 95% CI 0.51-0.65) and major adverse cardiovascular events (HR 0.54, 0.45-0.64), along with fewer heart failure admissions, heart attacks, and strokes. Incretin receptor agonists, the GLP-1 class, were also associated with lower mortality (HR 0.62, 0.52-0.74) and MACE (HR 0.75, 0.61-0.92). Indirect comparison showed no significant difference between the two strategies for all-cause mortality or stroke.
The headline numbers look impressive, but the authors rightly flag very low confidence across all comparisons, and that caveat deserves weight. Most included studies were observational, and surgical cohorts differ from drug-treated ones in ways statistics cannot fully erase: patients choosing surgery tend to be more motivated and often have different baseline risk, while drug cohorts increasingly include people with established cardiovascular disease. Trial evidence such as SELECT supports a real cardiovascular benefit from semaglutide, yet randomized data on surgery and hard outcomes remain scarce, so the surgical hazard ratios likely overstate the true effect. The network comparison is indirect and cannot settle which approach is better. The practical takeaway for adults with obesity is that effective, sustained weight loss by either route appears protective, and the choice should rest on degree of obesity, comorbidities, preference, and access rather than on a claimed winner. This is confirmatory rather than paradigm-shifting, and a head-to-head randomized trial remains the missing piece.